Overview

* Cronos Q2 2025 net revenue grows 21% yr/yr, misses analyst expectations

* Gross profit rises significantly due to higher sales prices and efficiencies

* Co reports net loss of $38.5 mln, impacted by foreign exchange losses

Outlook

* Cronos expects accelerated growth in H2 2025

* Company anticipates sales boost from Cronos GrowCo expansion in Fall 2025

* Company sees positive impact from anti-dumping duty veto in Israel

Result Drivers

* INTERNATIONAL DEMAND - Record international and Israel revenue driven by strong global demand for cannabis products

* CRONOS GROWCO CONTRIBUTION - Consolidation of Cronos GrowCo added $2.2 mln to Q2 2025 net revenue

* ISRAEL MARKET - Record revenue and sales volume in Israel driven by strong demand for high-quality medical cannabis and effective operations, per CEO Mike Gorenstein

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $2.21 $32.90

Revenue mln mln (1

Analyst)

Q2 Net -$38.48

Income mln

Q2 $1.69

Adjusted mln

EBITDA

Q2 Gross 43.0%

Margin

Q2 Capex $3.84

mln

Q2 Gross $14.50

Profit mln

Analyst Coverage

* The one available analyst rating on the shares is "buy"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)